AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
CANDESARTAN CILEXETIL
112 registrations across 9 African markets— 81 active
Markets with CANDESARTAN CILEXETIL
🇿🇦South Africa
33 registrations
24 active
🇹🇳Tunisia
22 registrations
0 active
🇬🇭Ghana
18 registrations
18 active
🇺🇬Uganda
16 registrations
16 active
🇹🇿Tanzania
11 registrations
11 active
🇳🇬Nigeria
4 registrations
4 active
🇲🇬Madagascar
4 registrations
4 active
🇿🇲Zambia
2 registrations
2 active
🇿🇼Zimbabwe
2 registrations
2 active
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Candesartan Cilexetil 8 mg Tablets Uncoated Tablet | 🇿🇲Zambia | Imperial Medical Solutions FZE | active | Apr 2031 |
| Candesartan Cilexetil 16 mg Tablets Uncoated Tablet | 🇿🇲Zambia | Imperial Medical Solutions FZE | active | Apr 2031 |
| NONE TABLET; ORAL | 🇿🇼Zimbabwe | IMPERIAL MEDICAL SOLUTIONS | active | Mar 2031 |
| NONE TABLET; ORAL | 🇿🇼Zimbabwe | IMPERIAL MEDICAL SOLUTIONS | active | Mar 2031 |
| ZYCARD 16mg TABLETS | 🇬🇭Ghana | — | active | Jul 2030 |
| ZYCARD 8mg TABLETS | 🇬🇭Ghana | — | active | Jul 2030 |
| ZYCARD 16mg TABLETS | 🇬🇭Ghana | — | active | Jul 2030 |
| ZYCARD 8mg TABLETS | 🇬🇭Ghana | — | active | Jul 2030 |
| ATACAND 8MG TABLETS | 🇬🇭Ghana | — | active | May 2030 |
| ATACAND 16MG TABLETS | 🇬🇭Ghana | — | active | May 2030 |
| ATACAND 16MG TABLETS | 🇬🇭Ghana | — | active | May 2030 |
| ATACAND 8MG TABLETS | 🇬🇭Ghana | — | active | May 2030 |
| ATACAND 32MG TABLETS | 🇬🇭Ghana | — | active | May 2030 |
| ATACAND 32MG TABLETS | 🇬🇭Ghana | — | active | May 2030 |
| CANDESAN 8mg TABLETS | 🇬🇭Ghana | — | active | May 2029 |
| CANDESAN TABLETS 8mg | 🇬🇭Ghana | — | active | May 2029 |
| CANDESAN 8mg TABLETS | 🇬🇭Ghana | — | active | May 2029 |
| CANDESAN TABLETS 8mg | 🇬🇭Ghana | — | active | May 2029 |
| ADVANT 8MG TABLETS | 🇬🇭Ghana | — | active | Jul 2028 |
| ADVANT 8MG TABLETS | 🇬🇭Ghana | — | active | Jul 2028 |
| ADVANT 16MG TABLETS | 🇬🇭Ghana | — | active | Jul 2028 |
| ADVANT 16MG TABLETS | 🇬🇭Ghana | — | active | Jul 2028 |
| Advant Tablet 16 mg** Tablet | 🇳🇬Nigeria | Getz Pharma Nigeria Limited | active | May 2028 |
| Advant Tablet 8 mg** Tablet | 🇳🇬Nigeria | Getz Pharma Nigeria Limited | active | May 2028 |
| Candesartan 8 mg Tablets Tablet | 🇳🇬Nigeria | Korlyns Pharmaceuticals Ltd | active | Dec 2026 |
| Candesartan 16 mg Tablets Tablet | 🇳🇬Nigeria | Korlyns Pharmaceuticals Ltd | active | Dec 2026 |
| CANDAGEN 16 | 🇿🇦South Africa | Ranbaxy Pharmaceutical (Pty) Ltd | suspended | Jun 2025 |
| CANDAGEN 8 | 🇿🇦South Africa | Ranbaxy Pharmaceutical (Pty) Ltd | suspended | Jun 2025 |
| ARTEWIN 32 mg | 🇿🇦South Africa | ZENTIVA SOUTH AFRICA (PTY) LTD | suspended | Feb 2023 |
| RAPHEX 8 mg | 🇿🇦South Africa | AstraZeneca Pharmaceuticals (Pty) Ltd | suspended | Nov 2022 |
| RAPHEX PLUS 16/12,5 mg | 🇿🇦South Africa | AstraZeneca Pharmaceuticals (Pty) Ltd | suspended | Nov 2022 |
| RAPHEX 32 mg | 🇿🇦South Africa | AstraZeneca Pharmaceuticals (Pty) Ltd | suspended | Nov 2022 |
| RAPHEX 16 mg | 🇿🇦South Africa | AstraZeneca Pharmaceuticals (Pty) Ltd | suspended | Nov 2022 |
| ARTEWIN 16 mg | 🇿🇦South Africa | ZENTIVA SOUTH AFRICA (PTY) LTD | suspended | Sept 2022 |
| ARTEWIN 8 mg | 🇿🇦South Africa | ZENTIVA SOUTH AFRICA (PTY) LTD | suspended | Sept 2022 |
| PRESSCAND Comprimé sécable / 8 mg | 🇹🇳Tunisia | PHARMACARE | expired | Apr 2022 |
| PRESSCAND Comprimé sécable / 16 mg | 🇹🇳Tunisia | PHARMACARE | expired | Apr 2022 |
| PRESSCAND Comprimé sécable / 4 mg | 🇹🇳Tunisia | PHARMACARE | expired | Apr 2022 |
| ARALEAD Comprimé pelliculé sécable / 32 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Dec 2019 |
| ARALEAD Comprimé pelliculé sécable / 32 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Dec 2019 |
| ARALEAD Comprimé pelliculé sécable / 16 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Jun 2019 |
| ARALEAD Comprimé pelliculé sécable / 16 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Jun 2019 |
| ARALEAD Comprimé pelliculé sécable / 8 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Feb 2019 |
| ARALEAD Comprimé pelliculé sécable / 8 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Feb 2019 |
| ARALEAD Comprimé pelliculé sécable / 4 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Feb 2019 |
| ARALEAD Comprimé pelliculé sécable / 4 mg | 🇹🇳Tunisia | NEAPOLIS PHARMA | expired | Feb 2019 |
| MONO-ETIKEN Comprimé sécable / 8 mg | 🇹🇳Tunisia | TAHA PHARMA | expired | Jun 2017 |
| MONO-ETIKEN Comprimé sécable / 4 mg | 🇹🇳Tunisia | TAHA PHARMA | expired | Jun 2017 |
| MONO-ETIKEN Comprimé sécable / 16 mg | 🇹🇳Tunisia | TAHA PHARMA | expired | Jun 2017 |
| MONO-ETIKEN Comprimé sécable / 32 mg | 🇹🇳Tunisia | TAHA PHARMA | expired | Jun 2017 |
Showing 50 of 112 registrations. Sign up free to search and export all.
CANDESARTAN CILEXETIL in Africa — Regulatory Overview
CANDESARTAN CILEXETIL is registered across 9 African markets with 112 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Tunisia, Ghana, Uganda and 5 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 112 registrations, 81 (72%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.